Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

An Update on Poly(ADP-ribose) Polymerase I-A Brief Review

Author(s): Preeya Negi, Kaviarasan Lakshmanan, Praveen Kumar Patel, Kalirajan Rajagopal and Gowramma Byran*

Volume 23, Issue 18, 2023

Published on: 22 March, 2023

Page: [1762 - 1771] Pages: 10

DOI: 10.2174/1389557523666230221145844

Price: $65

conference banner
Abstract

Poly (ADP-ribose) polymerase 1 (PARP1) plays important roles in both DNA repair and transcription, and the interplay of these processes in relation to cellular function and disease states has not been well defined. The tumor-suppressor effects of PARP inhibitors have attracted significant interest in the development of novel cancer therapies. As PARP1 binding motifs may be readily found in promoter elements of DNA repair genes, the expanding role of PARP1 in DNA repair does not have to be independent of transcription. The discovery of ADP-ribose binding modules that bind to various forms of mono- and poly-ADP-ribose has provided important insights into how ADPribosylation regulates different cellular pathways. Among the four distinct PAR-binding modules discovered so far, it is the macrodomain alone that, in addition to possessing binding activity, in some instances, also supports a catalytic activity toward ADP-ribose derivatives. However, the development of PARP inhibitors as chemopotentiating agents has been limited by an increase in observed toxicity, mainly myelosuppression, necessitating dose reduction of the cytotoxic chemotherapeutic agent and the PARP inhibitor. Hence, it presents an opportunity to rationally develop combinations of PARP inhibitors with new classes of DNA repair inhibitors that are on the horizon and classical cytotoxic agents. Clinical trials of PARP inhibitors are investigating various uses of these approaches in cancer. Recent studies on the clinical significance of PARP1 inhibitors are discussed in this review. These recent research advances will inform the selection of patient populations who can benefit from the PARP inhibitor treatment and the development of effective drug combination strategies.

« Previous Next »
Graphical Abstract

[1]
World Health Organization. Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer (Accessed March 25, 2022).
[2]
Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. Int. J. Cancer, 2021, 149(4), 778-789.
[http://dx.doi.org/10.1002/ijc.33588] [PMID: 33818764]
[3]
International agency for research on cancer. World Health Organization. Global cancer observatory. Available from: https://gco.iarc.fr/today (Accessed on: April 11, 2022).
[4]
National Cancer Institute. Dictionary of cancer terms. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor (Accessed on: April 11, 2022).
[5]
Thorsell, A.G.; Ekblad, T.; Karlberg, T.; Löw, M.; Pinto, A.F.; Trésaugues, L.; Moche, M.; Cohen, M.S.; Schüler, H. Structural basis for potency and promiscuity in poly(ADP-ribose) Polymerase (PARP) and tankyrase inhibitors. J. Med. Chem., 2017, 60(4), 1262-1271.
[http://dx.doi.org/10.1021/acs.jmedchem.6b00990] [PMID: 28001384]
[6]
Drugs.com Available from: https://www.drugs.com/drug-class/parp-inhibitors.html (Accessed on: April 11, 2022).
[7]
Weaver, A.N.; Yang, E.S. Beyond DNA Repair: Additional Functions of PARP-1 in Cancer. Front. Oncol., 2013, 3, 290.
[http://dx.doi.org/10.3389/fonc.2013.00290] [PMID: 24350055]
[8]
Herceg, Z.; Wang, Z.Q. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat. Res., 2001, 477(1-2), 97-110.
[http://dx.doi.org/10.1016/S0027-5107(01)00111-7] [PMID: 11376691]
[9]
Jain, P.G.; Patel, B.D. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. Eur. J. Med. Chem., 2019, 165, 198-215.
[http://dx.doi.org/10.1016/j.ejmech.2019.01.024] [PMID: 30684797]
[10]
Bai, P.; Cantó, C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab., 2012, 16(3), 290-295.
[http://dx.doi.org/10.1016/j.cmet.2012.06.016] [PMID: 22921416]
[11]
Ko, H.L.; Ren, E.C. Functional Aspects of PARP1 in DNA Repair and Transcription. Biomolecules, 2012, 2(4), 524-548.
[http://dx.doi.org/10.3390/biom2040524] [PMID: 24970148]
[12]
Szántó, M.; Bai, P. The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism. Genes Dev., 2020, 34(5-6), 321-340.
[http://dx.doi.org/10.1101/gad.334284.119] [PMID: 32029456]
[13]
Caporuscio, J. What to know about PARP inhibitors. 2021. Available from: https://www.medicalnewstoday.com/articles/parp-inhibitor (Accessedon: April 11, 2022).
[14]
Chambon, P.; Weill, J.D.; Mandel, P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun., 1963, 11(1), 39-43.
[http://dx.doi.org/10.1016/0006-291X(63)90024-X] [PMID: 14019961]
[15]
UniProt Available from: https://www.uniprot.org/uniprot/P09874 (Accessed on: April 30, 2022).
[16]
Pascal, J.M. The comings and goings of PARP-1 in response to DNA damage. DNA Repair, 2018, 71, 177-182.
[http://dx.doi.org/10.1016/j.dnarep.2018.08.022] [PMID: 30177435]
[17]
Langelier, M.F.; Planck, J.L.; Roy, S.; Pascal, J.M. Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: Structural and functional insights into DNA-dependent PARP-1 activity. J. Biol. Chem., 2011, 286(12), 10690-10701.
[http://dx.doi.org/10.1074/jbc.M110.202507] [PMID: 21233213]
[18]
Jeong, K.Y.; Park, M.H. The significance of targeting poly (adp-ribose) polymerase-1 in pancreatic cancer for providing a new therapeutic paradigm. Int. J. Mol. Sci., 2021, 22(7), 3509.
[http://dx.doi.org/10.3390/ijms22073509] [PMID: 33805293]
[19]
Zhu, H.; Wei, M.; Xu, J.; Hua, J.; Liang, C.; Meng, Q.; Zhang, Y.; Liu, J.; Zhang, B.; Yu, X.; Shi, S. PARP inhibitors in pancreatic cancer: Molecular mechanisms and clinical applications. Mol. Cancer, 2020, 19(1), 49.
[http://dx.doi.org/10.1186/s12943-020-01167-9] [PMID: 32122376]
[20]
Hanna, D.; Chopra, N.; Hochhauser, D.; Khan, K. The role of PARP inhibitors in gastrointestinal cancers. Crit. Rev. Oncol. Hematol., 2022, 171, 103621.
[http://dx.doi.org/10.1016/j.critrevonc.2022.103621] [PMID: 35124199]
[21]
Mani, C.; Tripathi, K.; Omy, T.R.; Reedy, M.; Manne, U.; Palle, K. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells. Biochim. Biophys. Acta Mol. Basis Dis., 2022, 1868(2), 166300.
[http://dx.doi.org/10.1016/j.bbadis.2021.166300] [PMID: 34748904]
[22]
Dellomo, A.J.; Abbotts, R.; Eberly, C.L.; Karbowski, M.; Baer, M.R.; Kingsbury, T.J.; Rassool, F.V. PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. Transl. Oncol., 2022, 15(1), 101283.
[http://dx.doi.org/10.1016/j.tranon.2021.101283] [PMID: 34808460]
[23]
Biegała, Ł.; Gajek, A.; Marczak, A.; Rogalska, A. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway. Biochim. Biophys. Acta Rev. Cancer, 2021, 1876(2), 188633.
[http://dx.doi.org/10.1016/j.bbcan.2021.188633] [PMID: 34619333]
[24]
Shroff, R.T.; Hendifar, A.; McWilliams, R.R.; Geva, R.; Epelbaum, R.; Rolfe, L.; Goble, S.; Lin, K.K.; Biankin, A.V.; Giordano, H.; Vonderheide, R.H.; Domchek, S.M. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO precision oncology, 2018, PO.17.00316.
[http://dx.doi.org/10.1200/PO.17.00316]
[25]
National Cancer Institute at the National Institutes of Health. News and events. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-olaparib-rucaparib-prostate-cancer (Accessed on: April 22, 2022).
[26]
U.S Food and Drug Administration. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/foundationoner-cdx-p170019s017 (Accessed on: April 22, 2022).
[27]
Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434(7035), 913-917.
[http://dx.doi.org/10.1038/nature03443] [PMID: 15829966]
[28]
Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.J.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; Martin, N.M.B.; Jackson, S.P.; Smith, G.C.M.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434(7035), 917-921.
[http://dx.doi.org/10.1038/nature03445] [PMID: 15829967]
[29]
Pommier, Y.; Murai, J. Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations. Ann. Oncol., 2015, 26(2), ii8-ii9.
[http://dx.doi.org/10.1093/annonc/mdv084.1]
[30]
Cohen-Armon, M. The modified phenanthridine PJ34 unveils an exclusive cell-death mechanism in human cancer cells. Cancers (Basel), 2020, 12(6), 1628.
[http://dx.doi.org/10.3390/cancers12061628] [PMID: 32575437]
[31]
Yu, J.; Gou, W.; Shang, H.; Cui, Y.; Sun, X.; Luo, L.; Hou, W.; Sun, T.; Li, Y. Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors. J. Enzyme Inhib. Med. Chem., 2022, 37(1), 952-972.
[http://dx.doi.org/10.1080/14756366.2022.2053524] [PMID: 35317687]
[32]
Cohen-Armon, M.; Yeheskel, A.; Pascal, J.M. Signal-induced PARP1-Erk synergism mediates IEG expression. Signal Transduct. Target. Ther., 2019, 4(1), 8.
[http://dx.doi.org/10.1038/s41392-019-0042-0] [PMID: 30993015]
[33]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02987543 (Accessed on: April 28, 2022).
[34]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02677038 (Accessed on: April 28, 2022).
[35]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03344965 (Accessed on: April 28, 2022).
[36]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT04330040 (Accessed on: April 28, 2022).
[37]
ClinicalTrials.gov provided by the U.S. National Library of Medicine.. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00753545 (Accessed on: April 28, 2022).
[38]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from https://clinicaltrials.gov/ct2/show/record/NCT02032823 (Accessed on: April 28, 2022).
[39]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01844986 (Accessed on: April 28, 2022).
[40]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01110603 (Accessed on: April 28, 2022).
[41]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02034916 (Accessed on: April 28, 2022).
[42]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02326844 (Accessed on: April 28, 2022).
[43]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01605162 (Accessed on: April 28, 2022).
[44]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01078662 (Accessed on: April 28, 2022).
[45]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02184195 (Accessed on: April 28, 2022).
[46]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03682289 (Accessed on: April 28, 2022).
[47]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03851614 (Accessed on: April 28, 2022).
[48]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02498613 (Accessed on: April 28, 2022).
[49]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03878524 (Accessed on: April 28, 2022).
[50]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01585805 (Accessed on: April 28, 2022).
[51]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00576654 (Accessed on: April 28, 2022).
[52]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03140670 (Accessed on: April 28, 2022).
[53]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03337087 (Accessed on: April 28, 2022).
[54]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03601923 (Accessed on: April 28, 2022).
[55]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03553004 (Accessed on: April 28, 2022).
[56]
ClinicalTrials.gov provided by the U.S. National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03404960 (Accessed on: April 28, 2022).
[57]
Chen, A. PARP inhibitors: Its role in treatment of cancer. Chin. J. Cancer, 2011, 30(7), 463-471.
[http://dx.doi.org/10.5732/cjc.011.10111] [PMID: 21718592]
[58]
Yu, J.; Luo, L.; Hu, T.; Cui, Y.; Sun, X.; Gou, W.; Hou, W.; Li, Y.; Sun, T. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2. Eur. J. Med. Chem., 2022, 227, 113898.
[http://dx.doi.org/10.1016/j.ejmech.2021.113898] [PMID: 34656898]
[59]
Clinical trials.gov provided by the U.S. national library of medicine.. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01989546 (Accessed on: April 28, 2022).
[60]
Kaviarasan, L.; Eldhose, E.; Krishnamurthy, P.T.; Rajagopal, K.; Mohammed, M.; Prudviraj, P.; Byran, G. 1,3,4-Thiadiazolo (3,2-A) Pyrimidine-6-Carbonitrile Scaffold as PARP1 Inhibitors. Anticancer. Agents Med. Chem., 2021, 21(15), 2050-2065.
[http://dx.doi.org/10.2174/1871520621666201216095018] [PMID: 33327923]
[61]
Li, H.; Hu, Y.; Wang, X.; He, G.; Xu, Y.; Zhu, Q. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation. Bioorg. Med. Chem., 2016, 24(19), 4731-4740.
[http://dx.doi.org/10.1016/j.bmc.2016.08.016] [PMID: 27561983]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy